Triesence Should NOT Be Injected Into Tear Ducts After Cataract Surgery
Triesence (triamcinolone acetonide) is NOT indicated for injection into tear ducts (lacrimal/canalicular system) and this route of administration is not supported by FDA labeling or clinical guidelines. The FDA-approved routes for Triesence are intravitreal injection for ophthalmic inflammatory conditions and visualization during vitrectomy 1.
FDA-Approved Routes of Administration
The FDA label for Triesence explicitly specifies only two approved uses 1:
- Intravitreal injection for ophthalmic inflammatory conditions (uveitis, sympathetic ophthalmia, temporal arteritis)
- Intravitreal injection for visualization during vitrectomy
The label provides detailed dosing for intravitreal administration (1-4 mg intravitreally) but makes no mention of tear duct, intracanalicular, or punctal administration 1.
Alternative Steroid Delivery Routes Post-Cataract Surgery
The 2022 AAO Cataract Preferred Practice Pattern guidelines acknowledge several alternative steroid delivery methods being studied, including intracanalicular delivery systems, but these are mentioned only in the context of research search terms—not as established recommendations 2. The guideline search strategy specifically includes "intracanalicular" as a term of interest for alternative drug delivery, but this refers to sustained-release devices placed in the canaliculus, not direct injection of Triesence.
Evidence-Based Alternatives Include:
Subconjunctival triamcinolone injection has demonstrated efficacy:
- A 2024 study showed subconjunctival TA (particularly 4 mg of 10 mg/ml formulation) reduced postoperative macular edema risk compared to topical steroids 3
- However, this route carries increased risk of prolonged steroid response, especially in glaucoma patients 4
Intracameral triamcinolone (into the anterior chamber):
- Proven safe and effective in pediatric cataract surgery 5, 6
- Provides excellent inflammation control when combined with shortened topical steroid courses 6
Posterior subtenon triamcinolone:
- Demonstrated superior inflammation control compared to topical steroids alone in pediatric cases 6
Critical Safety Considerations
Why Tear Duct Injection Is Inappropriate:
No FDA approval for this route—the label specifically states intravitreal administration only 1
Wrong anatomical target: Tear ducts drain tears away from the eye surface; injecting steroid here would not achieve therapeutic intraocular concentrations needed post-cataract surgery
Potential complications: Risk of canalicular obstruction, dacryocystitis, or systemic absorption without therapeutic benefit
Strict aseptic technique required: The FDA label emphasizes that Triesence injections must follow strict aseptic protocols with specific monitoring for IOP elevation and endophthalmitis 1—protocols designed for intravitreal, not canalicular, administration
Common Pitfall to Avoid:
Do not confuse intracanalicular sustained-release devices (which are being studied as alternatives to drops) with direct injection of Triesence into tear ducts. These are entirely different interventions—the former involves placing a dissolvable insert containing medication into the punctum/canaliculus, while the latter would be an off-label, unsupported use of an intravitreal suspension.
Recommended Approach
For post-cataract inflammation prophylaxis, use FDA-approved routes:
- Standard topical prednisolone acetate (with or without NSAIDs) remains the guideline-supported approach 2
- If considering dropless surgery, use subconjunctival triamcinolone (noting increased steroid response risk in glaucoma patients) 3, 4
- Intracameral triamcinolone at the time of surgery can reduce topical steroid burden 5, 6, 7
Screen patients carefully: Those with pre-existing glaucoma have 7-fold increased risk of steroid response and may not be suitable candidates for depot steroid formulations 3, 4.